A 3-month-old male infant was admitted to hospital with anemia. Followup controls revealed the presence of specific cytomegalovirus (CMV) antibodies. Virus was isolated from urine, blood, and saliva. At 7 months of age, he presented with melena. Polymerase chain reaction (PCR) of biopsy samples from the duodenum was positive for CMV. Anemia resolved after starting antiviral therapy with oral valganciclovir.
Case report
The patient was born in Rome, Italy, after an uncomplicated full-term pregnancy by spontaneous vaginal delivery with a birth weight of 2690 g (10th percentile for gestational age). The perinatal course was uneventful, and the infant was thriving while being exclusively breast-fed. Maternal serology during pregnancy revealed a protective immunoglobulin G (IgG) antibody titer against cytomegalovirus (CMV) and herpes simplex virus (HSV).
At the age of 8 weeks, he was hospitalized elsewhere for acute onset of fever, pallor, and tachypnea. At that time, laboratory investigations revealed hemoglobin of 8 g/dl, platelet count of 168 000/mm 3 , and leukocyte count 4500/mm 3 . Coagulation studies, renal function, transaminases, and albumin values were normal; hyperbilirubinemia was present with total serum bilirubin concentration of 9.6 mg/dl and direct bilirubin level of 1.0 mg/dl. Direct Coombs test was negative. The patient was treated with intravenous Ampicillin and Amikacin. Throat, urine, blood, and cerebrospinal fluid cultures were all negative. Serologic tests for Toxoplasma gondii, Parvovirus B19, Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus showed absence of IgM and IgG antibodies. Maternal transplacental IgG for HSV (12.00 index) and CMV (1600 UA/ml) were present. Urine and saliva cultures and serum PCR for CMV were negative. Chest and skull radiographs, cerebral ultrasonography, and ophthalmologic examination were normal. Within 24 h, fever disappeared and the general condition rapidly improved. Blood tests at discharge confirmed normocytic anemia (hemoglobin 7.7 g/dl) with reticulocyte count of 3.4% and normal iron and folate values.
After 13 days, at the age of about 3 months, he was admitted to our Onco-hematologic Pediatric Department; hemoglobin was 6.8 g/dl and on echocardiography, there was a mild septal dyskinesia. A red blood cell transfusion was performed. Congenital erythrocyte defects (glucose-6-phosphate dehydrogenase deficiency, thalassemia, and hereditary spherocytosis) and vitamin E deficiency were excluded.
After 4 weeks, at follow up, CMV-specific IgM and IgG antibodies were present (qualitative Enzygnost anti-CMV/IgM method; IgG 8.400 UA/ml Enzygnost anti-CMV/IgG. DADE Behring Marburg GmbH, Marburg, Germany). Virus was cultured from urine, blood and saliva too.
The baby was in good general condition, but was failing to thrive (height and length <3rd percentile for age and sex) and had persistent anemia. Screening for celiac disease using antiendomysium antibody (EMA) IgA, IgA anti-tissue transglutaminase (tTGA), serum IgA and IgE titer, specific serum IgE to cow's milk were normal; xylose absorption test was slightly abnormal (19 mg/dl, normal>20).
At the age of 7 months, he presented with melena. An upper gastrointestinal endoscopy revealed a normal appearing esophagus and stomach, but active bleeding in the duodenum that appeared grossly congested. Polymerase chain reaction performed by Q-CMV AmplyMIX MIEA (Amplimedical-BIOLINE, Turin, Italy) for CMV on blood and biopsy specimens from the duodenum was positive. Virus was cultured again from urine and saliva. IgG-specific CMV antibodies were 8700 UA/ml. Ophthalmologic examination showed no evidence of chorioretinitis and audiologic tests were also normal. Histological studies on duodenal biopsies showed patchy villous atrophy and flattened surface cells, and an eosinophilic infiltrate in the lamina propria.
The infant became unwell with recurrent gross or occult blood loss and persistent failure to thrive, so treatment with oral valganciclovir (15 mg/kg/dose thrice a day) was started. Oral valganciclovir was compounded from crushed tablets in a 1:1 mixture of Ora-Plus and Ora-Sweet syrup (manufactured by Paddock Laboratories, Minneapolis, MN USA). After 5 weeks of therapy, the baby presented neutropenia (leukocyte count 3190/mm 3 with 0.25/mm 3 polymorphonuclear leukocytes) and fever; blood sample revealed the presence of Streptococcus oralis infection, treated with a specific antibiotic (Cefepime). Valganciclovir therapy was discontinued. After 1 week, blood tests returned to normal values (hemoglobin b (Hgb) 10.8 g/dl, reticulocyte count 1.4%, leukocyte count 6450/mm 3 with 1500/ mm 3 polymorphonuclear leukocytes). Xylose absorption test was normal (42 mg/dl). At 8 weeks after the therapy, multiple biopsies of the duodenum consistently showed a normal appearance of the intestinal mucosa and PCR was negative for CMV.
At 14 months of age, the child is well with better growth parameters and is developmentally normal.
Discussion
CMV gastrointestinal disease secondary to perinatal infection is a rare condition in non-immunocompromised patients. We identified only a single published report, 1 in which a 6-week-old male infant presented a large upper gastrointestinal hemorrhage due to CMV infection.
Currently, three antivirals are licensed for treatment of CMV: ganciclovir and its prodrug, valganciclovir, foscarnet, and cidofovir. [2] [3] Reports suggest that ganciclovir is being used to treat selected infants with CMV disease; however, because of the potential bone marrow suppression and the reported long-term effects, such as testicular atrophy, it is recommended not to routinely use ganciclovir. [4] [5] In addition, only parenteral administration is possible. In March 2001, valganciclovir hydrochloride, the orally administered valyl ester of ganciclovir, was approved for use in adults 6 and some authors have used it for the treatment of symptomatic congenital CMV infections. 7 Valganciclovir is a prodrug that exists as a mixture of two diastereomers and is about 10 times more bioavailable than ganciclovir. The virustatic activity of ganciclovir is owing to an inhibition of viral DNA synthesis. Cytopenia (neutropenia, anemia, and thrombocytopenia) may occur at any time during treatment and may increase with continued dosing, but usually begins to recover within 3 to 7 days of discontinuing drug administration. Although liquid valganciclovir would be highly desirable, no commercial product is available. According to the indication of Henkin et al. 8 we obtained a 60 mg/ml oral liquid valganciclovir preparation, compounded from crushed tablets in a 1:1 mixture of Ora-Plus and Ora-Sweet (Paddock Laboratories, Minneapolis, MN USA). Ora-Plus is an aqueous-based vehicle consisting of a blend of suspending agents that have a high degree of colloidal activity. When combined in a 50/50 ratio with Ora-Sweet, the Ora-plus has increased palatability. The feasibility of oral administration represents a great improvement for pediatric patients because it is possible to easily adjust the drug dosage on the basis of the child's weight and to reduce the discomfort of the hospital stay.
The reported case adds more elements to the clinical spectrum of perinatal CMV infection and, in so far as the current findings are meaningful, it represents a good experience in the use of valganciclovir in pediatric patients. The limitations of a single case report with a relatively short follow-up emphasize the need for further studies to evaluate pharmacokinetics, efficacy, and safety of oral valganciclovir therapy in pediatric age.
